FDA Approves VP-102 for Molluscum Contagiosum

Article

The long-awaited approval for VP-102 makes this treatment the first available therapy for the pox virus-borne skin disease.

FDA Approves VP-102 for Molluscum Contagiosum

The US Food and Drug Administration (FDA) approved Verrica Pharmaceuticals’ drug candidate VP-102 (YCANTHE) for molluscum contagiosum treatment, making it the first treatment indicated for the viral-borne skin disease.1

The pharmaceutical company developed this drug-device combination product with a controlled formulation of cantharidin (0.7% w/v) that is designed to be administered through a single-use applicator for topical dosing and targeted delivery.

“We are proud to bring patients and caregivers the first FDA-approved treatment for molluscum, which is one of the largest unmet needs in medical dermatology,” Ted White, Verrica president and chief executive officer, said in the accompanying statement. “Verrica is the first company to develop a proprietary applicator and GMP-formulation of cantharidin that allows a safe, effective and precise topical administration, and the first company to successfully gain FDA approval after conducting rigorous clinical trials to evaluate the safe and effective use of a cantharidin-based product for the treatment of molluscum."

The New Drug Application (NDA) for this new treatment had been backed by data from the CAMP-1 and CAMP-2 clinical trials, which had shown a substantially higher rate of complete clearance of molluscum lesions and reduction in lesion count compared to the control arm at 84 days (P <.0001).2

Additional post-hoc analyses of the CAMP trials showed that a statistically significant greater proportion of the VP-102 arm achieved complete lesion clearance than vehicle across all affected body regions, including areas deemed most sensitive.

During these 2 trials, certain adverse events were noted in some of the participants who had been given VP-102, including pruritus, blistering, pain, and erythema at the application site. No serious adverse events were reported by treated patients.3

The PDUFA date for the drug’s approval had been set in February of 2023 when Verrica Pharmaceuticals accepted the NDA for VP-102.

Verrica had initially submitted their application for VP-102 to the FDA for this specific indication in 2021, but they received a Complete Response Letter (CRL) as a result of observed deficiencies at a contract manufacturing organization facility that was not involved in the drug's production.

However, the CRL announcement by Verrica emphasized that the treatment’s safety, clinical, or manufacturing properties were not found to be deficient by the FDA at the time. Besides its current use for this indication, VP-102 is also being assessed in another 2 mid-stage clinical trials for the treatment of common warts and external genital warts.

Recent late-breaking phase 3 data from B-SIMPLE showed berdazimer gel 10.3% treatment led to about 75% improvement in complete lesion clearance compared to vehicle and, specifically among children aged 6 to <12 years old, a complete clearance rate of 31.1% complete clearance rate versus 14.0% at 12 weeks.4

These findings, presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting in New Orleans, demonstrate that VP-102 and topical berdazimer are the 2 most promising potential treatments for molluscum contagiosum among children and adults.

Molluscum contagiosum is a pox virus-borne infection known to affect approximately 6 million people in the US, with children being the most commonly affected population and the greatest incidence being in children 1-14 years old.

References

  1. Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution 0.7%. News release. Verrica Pharmaceuticals. Published July 21, 2023. https://verrica.com/press_release/verrica-pharmaceuticals-announces-fda-approval-of-ycanth-cantharidin-topical-solution-0-7/
  2. Kunzmann, K. FDA Accepts New VP-102 Application for Molluscum Contagiosum. HCPLive. February 28, 2023. Accessed July 23, 2023.
  3. Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum. News release. Verrica Pharmaceuticals. February 27, 2023. https://verrica.com/press_release/fda-accepts-resubmitted-filing-for-vp-102-for-the-treatment-of-molluscum-contagiosum/
  4. Browning J et al. Efficacy of Berdazimer Gel 10.3% in the Treatment of Molluscum Contagiosum: Integrated Results from the B-SIMPLE Phase 3 Program. Paper presented at: American Academy of Dermatology 2023 Annual Meeting; March 17 – 21. New Orleans, LA. Accessed March 18, 2023.
Recent Videos
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
David Gozal, MD: Heterogeneity Poses Challenges to Diagnose Pediatric OSA
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
© 2024 MJH Life Sciences

All rights reserved.